Abstract
1 A comparison of total sulphapyridine saliva concentrations resulting from administration of sulphapyridine and sulphasalazine at equimolar doses has been carried out. It is concluded that the extent of azo reduction of sulphasalazine to release sulphapyridine is complete in healthy volunteers. 2 An ampicillin course of treatment alters the azo reduction of sulphasalazine. The extent of cleavage is reduced by one third on average. There is no change in the rate of absorption of the release sulphapyridine. 3 An ampicillin course of treatment does not alter the disposition of sulphapyridine. The changes noted in acetyl conjugate plasma concentrations are entirely consistent with reduced availability of sulphapyridine.
Full text
PDF![395](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5a9/1427633/f0bd68690cf3/brjclinpharm00189-0082.png)
![396](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5a9/1427633/9bc173cd0b49/brjclinpharm00189-0083.png)
![397](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5a9/1427633/6bb66bc0dfb5/brjclinpharm00189-0084.png)
![398](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5a9/1427633/3c1f4f60901e/brjclinpharm00189-0085.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Azad Khan A. K., Howes D. T., Piris J., Truelove S. C. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980 Mar;21(3):232–240. doi: 10.1136/gut.21.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
- Bates T. R., Blumenthal H. P., Pieniaszek H. J., Jr Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine. Clin Pharmacol Ther. 1977 Dec;22(6):917–927. doi: 10.1002/cpt1977226917. [DOI] [PubMed] [Google Scholar]
- DRUCKER M. M., BLONDHEIM S. H., WISLICKI L. FACTORS AFFECTING ACETYLATION IN-VIVO OF PARA-AMINOBENZOIC ACID BY HUMAN SUBJECTS. Clin Sci. 1964 Aug;27:133–141. [PubMed] [Google Scholar]
- Das K. M., Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet. 1976 Nov-Dec;1(6):406–425. doi: 10.2165/00003088-197601060-00002. [DOI] [PubMed] [Google Scholar]
- Day J. M., Houston J. B. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease. Br J Clin Pharmacol. 1980 Jan;9(1):91–94. doi: 10.1111/j.1365-2125.1980.tb04802.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dissanayake A. S., Truelove S. C. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut. 1973 Dec;14(12):923–926. doi: 10.1136/gut.14.12.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hansson K. A., Sandberg M. Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine. Acta Pharm Suec. 1973 Mar;10(1):87–92. [PubMed] [Google Scholar]
- Klotz U., Maier K., Fischer C., Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980 Dec 25;303(26):1499–1502. doi: 10.1056/NEJM198012253032602. [DOI] [PubMed] [Google Scholar]
- Peppercorn M. A., Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972 Jun;181(3):555–562. [PubMed] [Google Scholar]
- Schröder H., Campbell D. E. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539–551. doi: 10.1002/cpt1972134539. [DOI] [PubMed] [Google Scholar]
- Summers R. W., Switz D. M., Sessions J. T., Jr, Becktel J. M., Best W. R., Kern F., Jr, Singleton J. W. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979 Oct;77(4 Pt 2):847–869. [PubMed] [Google Scholar]
- van Hees P. A., Bakker J. H., van Tongeren J. H. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980 Jul;21(7):632–635. doi: 10.1136/gut.21.7.632. [DOI] [PMC free article] [PubMed] [Google Scholar]